Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAPDH | P04406 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL611982 | 0.86 | ROCK1 (0.46) | GAPDHHSD17B10KDM4EPOLBLMNA | |
| SCHEMBL608415 | 0.84 | GAA (0.51) | HSD17B10KDM4EPOLBLMNASMN1; SMN2 | |
| SCHEMBL611077 | 0.84 | TSPO (0.40) | GAPDHHSD17B10KDM4EPOLBLMNA | |
| SCHEMBL612231 | 0.82 | KMT2A (0.46) | HSD17B10KDM4EPOLBSMN1; SMN2MEN1 | |
| SCHEMBL612415 | 0.81 | GAA (0.46) | HSD17B10KDM4ELMNAMEN1KMT2A | |
| SCHEMBL610138 | 0.80 | WNT3A (0.47) | HSD17B10KDM4ELMNASMN1; SMN2KMT2A | |
| SCHEMBL610485 | 0.79 | GABRA1 (0.48) | HSD17B10KDM4ELMNAPDE4DHPGD | |
| SCHEMBL611044 | 0.78 | TSPO (0.43) | HSD17B10KDM4ELMNAMEN1KMT2A | |
| SCHEMBL612631 | 0.78 | KMT2A (0.53) | HSD17B10KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL610335 | 0.77 | POLB (0.55) | HSD17B10KDM4EPOLBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040979-A1 | IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS | FALCO JOSE LUIS (ES) | 2012-02-16 | — | — | US | claimed |
| EP-2010536-B1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INT (ES) | 2010-06-16 | — | — | EP | claimed |
| US-20090176788-A1 | Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions | FERRER INTERNACIONAL, S.A. (ES) | 2009-07-09 | — | — | US | claimed |
| EP-2010536-A1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | Ferrer Internacional, S.A. (ES) | 2009-01-07 | — | — | EP | claimed |
| EP-1845098-A1 | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-17 | — | — | EP | claimed |
| WO-2007110437-A1 | IMIDAZO [1, 2-B] PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-04 | — | — | WO | claimed |
| US-8993562-B2 | Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2015-03-31 | — | — | US | disclosed |
| US-8153789-B2 | Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2012-04-10 | — | — | US | disclosed |
| US-20120040979-A1 | IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS | FALCO JOSE LUIS (ES) | 2012-02-16 | — | — | US | disclosed |
| EP-2010536-B1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INT (ES) | 2010-06-16 | — | — | EP | disclosed |
| US-20090176788-A1 | Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions | FERRER INTERNACIONAL, S.A. (ES) | 2009-07-09 | — | — | US | disclosed |
| EP-2010536-A1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | Ferrer Internacional, S.A. (ES) | 2009-01-07 | — | — | EP | disclosed |
| EP-1845098-A1 | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007110437-A1 | IMIDAZO [1, 2-B] PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176788-A1 | Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions | GABRA5, GABRA1, GABRA2 | GAPDH 3298/4885HSD17B10 1290/4885KDM4E 2511/4885 |
| US-20120040979-A1 | IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS | GABRA5, GABRA1, GABRA2 | GAPDH 3298/4885HSD17B10 1290/4885KDM4E 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.